ARS Pharmaceuticals
SPRY
62 hedge funds and large institutions have $1.13B invested in ARS Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.26% more ownership
Funds ownership: 0% → 70.26% (+70%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$292M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$84.6M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$58.2M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$56M |
Top Sellers
SPRY Hedge Fund Activity: Q4 2020 in Review
62 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2020, worth a combined $1.13B.
Buyers outnumbered sellers: 62 funds opened new SPRY positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $292M.
- 62 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.13B of ARS Pharmaceuticals stock for Q4 2020.
- 62 funds opened new ARS Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +62 holders.
- The largest ARS Pharmaceuticals buyer in Q4 2020 was OrbiMed, an estimated $292M added.
Based on aggregated 13F filings for Q4 2020.